Rituximab induced literature review 325 cases of adverse reactions.doc

 PAGE \* MERGEFORMAT 9 Rituximab induced literature review 325 cases of adverse reactions Of: Chen, Ko Wing-Yan, Li Yan Leung Chi Hung [Abstract] Objective To investigate the anti-tumor targeted drug rituximab (MabThera) characteristics and rules of adverse reactions, clinical safety, rational use of available information. Method of retrospective research methods, the use of China Academic Journal from 1999 to 2009 of rituximab reported cases of adverse reactions were analyzed. Results adverse reactions were infusion reactions, and mainly in the 1st infusion. Conclusion Rituximab treatment should be intensive care, to ensure drug safety . [Keywords:] Rituximab; rituximab; adverse reactions Abstract: Objective To investigate the adverse reactions of rituximab (Rituxan ?q and MabThera ?q) in retrospection to provide references for safe and rational drug use clinically. Methods A retrospective analysis was conducted on adverse reactions of rituximab during the period from 1999 to 2009 retrieved from CNKI database. Results The main ADRs were infusion reactions, and occurred mainly in the first intravenous drip. Conclusion The use of rituximab treatment should be closely monitored to ensure the safety of drug use. Keywords:: rituximab; Rituxan ?q and MabThera ?q; adverse drug reactions Rituximab (MabThera) as the first clinical application of anti-CD20 chimeric monoclonal antibody Long, B lymphocytes in the treatment of malignant diseases has been fully proved, greatly changed the CD20-positive B-cell lymphoma The efficacy and prognosis. rituximab compared with traditional chemotherapy drugs less adverse reactions. In this paper, from 1999 to 2009, all domestic medical journals reported use of rituximab for treatment of adverse reactions caused by statistical analysis to order to facilitate the clinical use of rituximab to provide better medication monitoring, to ensure drug safety. 1 Materials and Methods By “rituximab,” “rituximab,” as keyw